Clinical Trials Directory

Trials / Completed

CompletedNCT02244762

Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Extended-Release (HC-ER) in Subjects With Renal Impairment

Evaluation of the Effect of Renal Impairment on the Pharmacokinetics and Metabolism of Hydrocodone and Its Metabolites Following Administration of Hydrocodone Bitartrate Extended-Release (HC-ER) 20 mg Capsules

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
37 (actual)
Sponsor
Zogenix, Inc. · Industry
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Accepted

Summary

Determine the influence of renal impairment on the pharmacokinetics and metabolism of Hydrocodone Bitartrate Extended-Release (HC-ER) 20 mg capsules

Detailed description

Pharmacokinetics and relative bioavailability of hydrocodone and its metabolites under fasted conditions

Conditions

Interventions

TypeNameDescription
DRUG20 mg HC-ER1-72 hours
DRUG20 mg HC-ER1-72 hours
DRUG20 mg HC-ER1-72 hours

Timeline

Start date
2011-02-01
Primary completion
2011-05-01
Completion
2011-05-01
First posted
2014-09-19
Last updated
2022-11-10

Source: ClinicalTrials.gov record NCT02244762. Inclusion in this directory is not an endorsement.